Wolverine Trading’s Catalyst Pharmaceutical CPRX Stock Holding History

Wolverine Trading’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-10,609	Closed	-$164K	–	4860
2024 Q2	$164K	Buy	+10,609	New	+$165K	﹤0.01%	3914
2023 Q1	–	Sell	-21,048	Closed	-$347K	–	4333
2022 Q4	$391K	Buy	+21,048	New	+$324K	﹤0.01%	2545
2021 Q2	–	Sell	-15,622	Closed	-$68K	–	6107
2021 Q1	$68K	Sell	15,622 -3,608	-19%	-$14.3K	﹤0.01%	5568
2020 Q4	$66K	Buy	+19,230	New	+$64.6K	﹤0.01%	4563
2020 Q2	–	Sell	-30,126	Closed	-$117K	–	4652
2020 Q1	$117K	Buy	+30,126	New	+$124K	﹤0.01%	3952
2019 Q4	–	Sell	-23,040	Closed	-$108K	–	4718
2019 Q3	$121K	Buy	+23,040	New	+$123K	﹤0.01%	3793
2018 Q4	–	Sell	-31,057	Closed	-$117K	–	4543
2018 Q3	$117K	Buy	+31,057	New	+$97.3K	﹤0.01%	4482

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Wolverine Trading's CPRX Position: Q3 2024 in Review

Wolverine Trading sold out of Catalyst Pharmaceutical (CPRX) in Q3 2024, closing a stake of 10,609 shares — an estimated $164K sold.

Wolverine Trading first reported a position in CPRX in Q3 2018 and held it in 7 quarters. The position peaked at $391K in Q4 2022. 316 funds tracked by Wall St. Rank hold CPRX as of Q3 2024.

Wolverine Trading reported no remaining Catalyst Pharmaceutical position as of Q3 2024 after selling out during the quarter.
Wolverine Trading sold 10,609 Catalyst Pharmaceutical shares in Q3 2024, an estimated $164K.
Wolverine Trading first reported a position in Catalyst Pharmaceutical in Q3 2018 and held it in 7 quarters.
Wolverine Trading's Catalyst Pharmaceutical position peaked at $391K in Q4 2022.
316 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2024.

Based on Wolverine Trading's 13F filing for Q3 2024, filed 14 Nov 2024.